Peripherally Inserted Central Venous Catheter (PICC)

Summary and conclusions

In severely ill patients, central venous lines (catheter and venous port) are often used to deliver drugs, supply nutrients, or draw blood samples. A peripherally inserted central venous catheter (PICC/PICC line) is a type of central venous line. It is a long, thin catheter constructed of flexible material, often silicone or polyurethane, inserted into a vein in the arm and threaded through the vascular system to the central veins in the chest. Although evidence concerning the method remains unclear, the use of PICC in Swedish health care is increasing because PICC is considered to require fewer resources than conventional central venous catheters.

SBU’s appraisal of the evidence

- Too few studies of sufficiently high quality are available to appraise the functionality of the method, or how often PICC has successfully established central venous access when compared to other central venous lines.

- Likewise, the evidence is insufficient to compare complication risks or patient experiences. The findings suggest a potentially higher risk of deep vein thrombosis, but a potentially lower risk of catheter occlusion, when using PICC.

- Since the medical effects have not been sufficiently studied, the cost-effectiveness of the method cannot be appraised. Studies of high quality are essential to investigate the clinical benefits, risks, and cost-effectiveness of PICC.

Technology and target group

Central venous lines are often used in patients with severe conditions involving, e.g. surgery, anaesthesiology, intensive care, and oncology/haematology. Clinicians use different types of central venous catheters, e.g. tunnelled and non-tunnelled central venous catheters (CVC) or subcutaneous venous ports, depending on the indications and how long the patient will require a central venous line. Insertion of a central venous line requires a physician performing the procedure, mostly in an intensive care unit or an operating theatre.

Insertion of a central venous line carries a risk for serious complications, e.g. pneumothorax, haemorrhage, stroke, and nerve damage. While in use, other complications could also arise, e.g. infection, thrombosis, and catheter occlusion. Serious complications per se, or delayed treatment, can lead to increased suffering for patients and, in some cases, even a fatal outcome. Complications also lead to higher costs, among other things due to the increased need for care.

In recent years, more health care units have started using PICC [1]. A conceivable reason is an increased need for central venous lines. Also, since operating units have a limited capacity for inserting these lines, patients may need to wait for a central venous line. The asserted advantages of using PICCs are that they, compared to other central venous lines, could have fewer serious complications. Also, specially trained nurses can insert the PICC line outside of an operating theatre.

Target groups for PICC are patients in need of treatment involving, e.g. antibiotics, cytostatic drugs (chemotherapy), and nutritional solutions.

Primary questions

- What are the advantages and disadvantages of PICC compared to other central venous lines in terms of early and delayed complications, patient satisfaction, quality of life, functionality, and successful insertion rates in patients needing central venous lines?

- What does treatment cost?

- Is treatment cost-effective?
**Patient benefit**

- The scientific evidence is insufficient, i.e. studies of sufficiently high quality are not available to draw conclusions on PICC compared to other central venous lines, as regards early and delayed complications, patient satisfaction, quality of life, functionality, and success rates of insertion in patients needing central venous lines (★★★★).

This systematic literature review includes 11 studies, 2 of these are of medium quality and serve as a basis for the conclusions. The remaining 9 studies were found to be of low quality. Both of the medium-quality studies are cohort studies that compared PICC to other types of central venous lines. One of these studies, which investigated children and adolescents receiving chemotherapy, reported that PICC presents a higher risk for symptomatic deep vein thrombosis. The results also showed that patients with a PICC were at lower risk for catheter occlusion. The second study, comprised of adult patients discharged from intensive care units for further care at other units, showed that patients with a PICC were at higher risk for deep vein thrombosis. Combined, these findings suggest that PICC could involve a higher risk for deep vein thrombosis, but possibly a lower risk for catheter occlusion. However, additional high-quality studies need to confirm these findings before valid conclusions can be drawn.

**Economic aspects**

- Since the evidence concerning medical outcomes is insufficient, the cost-effectiveness of using PICCs cannot be appraised.

Four levels are used in grading the strength of the scientific evidence on which conclusions are based:

- **Strong scientific evidence (★★★★).** Based on high or medium quality studies with no factors that weaken the overall assessment.
- **Moderately strong scientific evidence (★★★★).** Based on high or medium quality studies with isolated factors that weaken the overall assessment.
- **Limited scientific evidence (★★★★).** Based on high or medium quality studies having factors that weaken the overall assessment.
- **Insufficient scientific evidence (★★★★).** Scientific evidence is deemed insufficient when scientific findings are absent, the quality of available studies is low, or studies of similar quality present conflicting findings.

References
SBU evaluates healthcare technology
The Swedish Council on Health Technology Assessment (SBU) is a national governmental agency that assesses healthcare technologies. SBU analyses the benefits, risks, and costs of different methods and compares the scientific facts to prevailing practices in Sweden. SBU’s goal is to provide stronger evidence for everyone engaged in shaping the delivery of health services.

The SBU Alert reports are produced in collaboration with experts from the respective subject areas, the National Board of Health and Welfare, the Medical Products Agency, the Swedish Association of Local Authorities and Regions, and a special advisory panel (the Alert Advisory Board).

This assessment was published in 2011. Findings based on strong scientific evidence usually continue to apply well into the future. However, findings based on insufficient, limited, or contradictory evidence might have already been replaced by more recent findings.

The complete report is available in Swedish.

The Alert Advisory Board
Jan-Erik Johansson, Chairman, Professor
Christel Bahtsevani, PhD
Lars Borgquist, Professor
Bo Carlberg, Associate Professor
Jane Carlsson, Professor
Per Carlsson, Professor
Björn-Erik Erlandsson, Professor
Mårten Fernö, Professor
Lennart Iselius, Associate Professor
Viveca Odland, Professor
Anders Rydh, Associate Professor
Anders Tegnell, PhD
Jan Wahlström, Professor Emeritus
Anna Åberg Wistedt, Professor

SBU Board Subcommittee
Susanna Axelsson, David Bergqvist, Håkan Ceder,
Tove Livered, Jan Liliemark, Nina Rehnqvist,
Måns Rosén, Ewalotte Ränzlöv, Sofia Tranæus

Publisher: Måns Rosén, Director, SBU
Program Manager: Sofia Tranæus, SBU
Graphic Production: Anna Edling, SBU